Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed)
National Institutes of Health
Award ceiling
—Award floor
—Posted
Dec 6, 2024Closes
Jul 2, 2027Location eligibility
No specific state restriction found in this listing — check the full opportunity for details.Categories: Health
Eligible applicants: Others (see text field entitled "Additional Information on Eligibility" for clarification), Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, Special district governments, Native American tribal organizations (other than Federally recognized tribal governments), State governments, For profit organizations other than small businesses, Public and State controlled institutions of higher education, County governments, Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Independent school districts, City or township governments, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Private institutions of higher education, Small businesses
Description
This notice of funding opportunity (NOFO) provides funding to conduct efficacy studies in an established rare disease preclinical model to demonstrate that a proposed therapeutic agent warrants further development. In addition to preclinical efficacy, accompanying pharmacodynamic and pharmacokinetic studies would be supported. Therapeutic agents include small molecules, biologics or biotechnology-derived products. The goal of this NOFO is to spur therapeutic development for a variety of rare diseases by advancing projects to the point where they would attract subsequent investment supporting full Investigational New Drug (IND) application development or progression to clinical trials in the case of repurposing or repositioning.